Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bendamustine Hydrochloride

FDA-approved product (powder, intravenous), marketed as Belrapzo, Bendamustine Hydrochloride, Bendeka and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Bendamustine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Neoplasm
  • Neoplasm of mature B-cells
  • Non-Hodgkins lymphoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nitrogen mustard analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bendamustine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bendamustine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)

    NCT04942730 · start 2021-01-21

    Registered record
    Registry ID
    NCT04942730
    Conditions
    Leukemia, Acute Lymphoblastic; Myeloid Leukemia, Acute; Biphenotypic Acute Leukemia; Lymphoblastic Lymphoma; Myelodysplastic Syndromes; Myeloproliferative Neoplasm
    Interventions
    Fludarabine; Bendamustine Hydrochloride; Busulfan; Cyclophosphamide; Mycophenolate Mofetil; Tacrolimus 5Mg Cap
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-01-21
    Completion
    2024-04-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia, Acute Lymphoblastic; Myeloid Leukemia, Acute; Biphenotypic Acute Leukemia; Lymphoblastic Lymphoma +2 more
    InterventionFludarabine; Bendamustine Hydrochloride; Busulfan; Cyclophosphamide +2 more
    PhasePhase 2
    Registry statusCompleted

  • Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

    NCT04607772 · start 2020-11-18

    Registered record
    Registry ID
    NCT04607772
    Conditions
    Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Interventions
    Selinexor; Rituximab; Bendamustine; Polatuzumab Vedotin; Ibrutinib; Lenalidomide; Tafasitamab; Venetoclax; Gemcitabine; Oxaliplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2020-11-18
    Completion
    2025-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory Diffuse Large B-Cell Lymphoma
    InterventionSelinexor; Rituximab; Bendamustine; Polatuzumab Vedotin +6 more
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

    NCT04083495 · start 2019-09-17

    Registered record
    Registry ID
    NCT04083495
    Conditions
    Peripheral T Cell Lymphoma
    Interventions
    ATLCAR.CD30 T cells; Bendamustine; Fludarabine; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2019-09-17
    Completion
    2038-08
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral T Cell Lymphoma
    InterventionATLCAR.CD30 T cells; Bendamustine; Fludarabine; Cyclophosphamide
    PhasePhase 2
    Registry statusRecruiting

  • Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL

    NCT03787264 · start 2019-01-14

    Registered record
    Registry ID
    NCT03787264
    Conditions
    Chronic Lymphoid Leukemia
    Interventions
    Bendamustine; Obinutuzumab; Acalabrutinib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-01-14
    Completion
    2023-09-26
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphoid Leukemia
    InterventionBendamustine; Obinutuzumab; Acalabrutinib; Venetoclax
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

    NCT03593018 · start 2018-11-09

    Registered record
    Registry ID
    NCT03593018
    Conditions
    Relapsed Angioimmunoblastic T-Cell Lymphoma; Refractory Angioimmunoblastic T-cell Lymphoma
    Interventions
    Oral azacitidine; Romidepsin; Bendamustine; Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-11-09
    Completion
    2025-08-28
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Angioimmunoblastic T-Cell Lymphoma; Refractory Angioimmunoblastic T-cell Lymphoma
    InterventionOral azacitidine; Romidepsin; Bendamustine; Gemcitabine
    PhasePhase 3
    Registry statusCompleted

  • A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

    NCT03352765 · start 2017-11-20

    Registered record
    Registry ID
    NCT03352765
    Conditions
    Lymphoma
    Interventions
    rituximab; bendamustine; melphalan; Autologous Stem Cell Transplantation (ASCT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2017-11-20
    Completion
    2026-11
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionrituximab; bendamustine; melphalan; Autologous Stem Cell Transplantation (ASCT)
    PhasePhase 1
    Registry statusActive not recruiting

  • CyBeR Association in Relapsed/Refractory DLBCL

    NCT02758925 · start 2016-06

    Registered record
    Registry ID
    NCT02758925
    Conditions
    Diffuse Large B Cell Lymphoma
    Interventions
    Rituximab; Bendamustine; Cytarabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-06
    Completion
    2018-12
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B Cell Lymphoma
    InterventionRituximab; Bendamustine; Cytarabine
    PhasePhase 2
    Registry statusUnknown

  • BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation

    NCT03315520 · start 2016-01-22

    Registered record
    Registry ID
    NCT03315520
    Conditions
    Relapsed/Refractory Malignant Lymphomas
    Interventions
    Bendamustine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-01-22
    Completion
    2020-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed/Refractory Malignant Lymphomas
    InterventionBendamustine
    PhasePhase 2
    Registry statusUnknown

  • Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma

    NCT02420210 · start 2015-11

    Registered record
    Registry ID
    NCT02420210
    Conditions
    Diffuse Large B-Cell Lymphoma
    Interventions
    Bendamustine Hydrochloride; Obinutuzumab; Dexamethasone; Quality-of-Life Assessment; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-11
    Completion
    2016-08
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B-Cell Lymphoma
    InterventionBendamustine Hydrochloride; Obinutuzumab; Dexamethasone; Quality-of-Life Assessment +1 more
    PhasePhase 2
    Registry statusTerminated

  • Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

    NCT02445131 · start 2015-05-28

    Registered record
    Registry ID
    NCT02445131
    Conditions
    Chronic Lymphocytic Leucemia
    Interventions
    Bendamustine; GA101; CAL-101
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-05-28
    Completion
    2022-03-09
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leucemia
    InterventionBendamustine; GA101; CAL-101
    PhasePhase 2
    Registry statusCompleted

  • Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

    NCT02348216 · start 2015-04-21

    Registered record
    Registry ID
    NCT02348216
    Conditions
    Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B-Cell Lymphoma; Transformed Follicular Lymphoma (TFL); Primary Mediastinal B-cell Lymphoma (PMBCL); High Grade B-cell Lymphoma (HGBCL)
    Interventions
    Axicabtagene Ciloleucel; Fludarabine; Cyclophosphamide; Levetiracetam; Tocilizumab; Dexamethasone; High-dose methylprednisolone; Bendamustine; Rituximab; Doxorubicin; Prednisone; Vincristine; Ifosfamide; Carboplatin; Etoposide; Gemcitabine; Oxaliplatin; Cisplatin; Methylprednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-04-21
    Completion
    2023-07-27
    Enrolment
    307

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B-Cell Lymphoma; Transformed Follicular Lymphoma (TFL); Primary Mediastinal B-cell Lymphoma (PMBCL) +1 more
    InterventionAxicabtagene Ciloleucel; Fludarabine; Cyclophosphamide; Levetiracetam +15 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)

    NCT02194374 · start 2015-01

    Registered record
    Registry ID
    NCT02194374
    Conditions
    Leukemia
    Interventions
    ROR1R-CAR-T Cell Infusion; Fludarabine; Cyclophosphamide; Rituximab; Bendamustine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2015-01
    Completion
    2017-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionROR1R-CAR-T Cell Infusion; Fludarabine; Cyclophosphamide; Rituximab +1 more
    PhasePhase 1
    Registry statusWithdrawn

  • A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

    NCT02187861 · start 2014-12-01

    Registered record
    Registry ID
    NCT02187861
    Conditions
    Follicular Lymphoma
    Interventions
    Venetoclax; Bendamustine; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-12-01
    Completion
    2018-03-16
    Enrolment
    163

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Lymphoma
    InterventionVenetoclax; Bendamustine; Rituximab
    PhasePhase 2
    Registry statusCompleted

  • Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

    NCT02315157 · start 2014-06

    Registered record
    Registry ID
    NCT02315157
    Conditions
    Multiple Myeloma; Plasma Cell Leukemia
    Interventions
    Bendamustine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2014-06
    Completion
    2018-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma; Plasma Cell Leukemia
    InterventionBendamustine
    PhasePhase 1
    Registry statusWithdrawn

  • Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

    NCT02006485 · start 2013-12-13

    Registered record
    Registry ID
    NCT02006485
    Conditions
    Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma
    Interventions
    Ublituximab + TGR-1202; Ublituximab + TGR-1202 + ibrutinib; Ublituximab + TGR-1202 + bendamustine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-12-13
    Completion
    2019-10
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma
    InterventionUblituximab + TGR-1202; Ublituximab + TGR-1202 + ibrutinib; Ublituximab + TGR-1202 + bendamustine
    PhasePhase 1
    Registry statusCompleted